Movin' On Out

Article

Pharmaceutical Technology Europe

Pharmaceutical Technology EuropePharmaceutical Technology Europe-08-01-2011
Volume 23
Issue 8

Visiting a new site or going down memory lane may not get you where you want to go.

By Control, a senior compliance officer

Visiting a new site or going down memory lane may not get you where you want to go.

This article was also published in our US sister publication Pharmaceutical Technology and can be read here.

Articles in this issue
Improving API Synthesis
Understanding Fluidized-Bed Granulation
Controlled Release from Porous Platforms
Controlled Crystallization During Freeze-Drying
Movin' On Out
The Many Varieties Of 'Emerging'
The Many Varieties Of 'Emerging'
News
Managing Information Overload
Managing Information Overload
The Importance Of Filter Testing
The Importance Of Filter Testing
Making A Mark In Emerging Markets
Making A Mark In Emerging Markets
Croatia, Pharma and Corruption
Croatia, Pharma and Corruption
i1-732715-1408617687064.jpg
Gene-ius
The Challenges Of The Emerging Markets
The Challenges Of The Emerging Markets
Recent Videos
Tore Bergsteiner from MAIN5 details his predictions for how the mega trends will shape the bio/pharma industry in 2025 and beyond.
Roger Viney from ICE Pharma discusses the quality and compliance issues surrounding the use of animal-derived ingredients in the bio/pharma industry.
Related Content
Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - stock.adobe.com

Benuvia Awarded NIH Contract for GMP Synthesis of Psilocybin, Other Drug Substances

Patrick Lavery
March 25th 2025
Article

The contract will support R&D of high-quality APIs for substance use disorders and mental health conditions, starting with synthesis and scale-up of psilocybin, which is derived from mushrooms.

Drug Solutions Podcast: Equipment Trends for Addressing Production of New Modalities

Drug Solutions Podcast: Equipment Trends for Addressing Production of New Modalities

Feliza Mirasol
March 25th 2025
Podcast

The growing development of new biotherapeutic modalities will rely heavily on automation and progressive technologies.

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - stock.adobe.com

FDA Approves Novartis Oral Treatment for Adults with C3 Glomerulopathy

Patrick Lavery
March 25th 2025
Article

Fabhalta (iptacopan) received a positive opinion for treatment of C3G from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) and has been approved twice before by FDA.

Drug Solutions Podcast: Forecasting Pharma’s Future

Drug Solutions Podcast: Forecasting Pharma’s Future

Felicity Thomas
January 31st 2025
Podcast

This episode is a compilation of comments taken from a series of interviews where experts reveal the trends that have impacted the bio/pharma industry in 2024 and those they expect to be impactful in 2025.

Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

Latigo Biotherapeutics Raises $150 Million to Advance Non-Opioid Pain Therapeutics

Feliza Mirasol
March 24th 2025
Article

With financing led by Blue Owl Capital, Latigo will use the funds to further develop non-opioid pain treatments as well as develop other candidates in its pipeline.

DCAT Week 2025: Sustainability in Medical Propellants

DCAT Week 2025: Sustainability in Medical Propellants

Patrick Lavery
March 24th 2025
Article

PharmTech Group chatted with Markus Laubscher of Orbia during DCAT Week 2025, covering the topics of sustainability, regulatory hurdles, next-generation innovation, and the DCAT Week experience.